(19) World Intellectual Property Organization

International Bureau



) TRANS BUNGTON IN BURNE NOON BURNE BURNE BOOK IN DIE BURNE BURNE

(43) International Publication Date -12 August 2004 (12.08.2004) --

(10) International Publication Number **WO 2004/066961 A3**

(51) International Patent Classification7: C12Q 1/70

A61K 39/12,

(21) International Application Number:

PCT/US2004/000635

- (22) International Filing Date: 12 January 2004 (12.01.2004)
- (25) Filing Language:

English

(26) Publication Language:

English

(30) Priority Data: 60/441,369

20 January 2003 (20.01.2003)

- (71) Applicant (for all designated States except US): ST. JUDE CHILDREN'S RESEARCH HOSPITAL [US/US]; 332 North Lauderdale Street, Office Of Technology Licensing, Mail Stop 742, Memphis, TN 38105 (US).
- (71) Applicants and
- (72) Inventors: HURWITZ, Julia [US/US]; 1846 Hunters Hill Drive, Germantown, TN 38138 (US). SLOBOD, Karen [US/US]; 2463 Madison Avenue, Memphis, TN 38112 (US). PORTNER, Allen [US/US]; 2752 Galaxie, Bartlett, TN 38134 (US). COLECLOUGH, Christopher [US/US]; 1843 Hunters Hill Drive, Germantown, TN 38138 (US).
- (74) Agent: ELMER, James, Scott; 332 North Lauderdale Street, Office Of Technology Licensing, Mail Stop 742, Memphis, TN 38105 (US).
- (81) Designated States (unless otherwise indicated, for every kind of national protection available): AE, AG, AL, AM,

AT, AU, AZ, BA, BB, BG, BR, BW, BY, BZ, CA, CH, CN, CO, CR, CU, CZ, DE, DK, DM, DZ, EC, EE, EG, ES, FI, GB, GD, GE, GH, GM, HR, HU, ID, IL, IN, IS, JP, KE, KG, KP, KR, KZ, LC, LK, LR, LS, LT, LU, LV, MA, MD, MG, MK, MN, MW, MX, MZ, NA, NI, NO, NZ, OM, PG, PH, PL, PT, RO, RU, SC, SD, SE, SG, SK, SL, SY, TJ, TM, TN, TR, TT, TZ, UA, UG, US, UZ, VC, VN, YU, ZA, ZM, ZW.

(84) Designated States (unless otherwise indicated, for every kind of regional protection available): ARIPO (BW, GH, GM, KE, LS, MW, MZ, SD, SL, SZ, TZ, UG, ZM, ZW), Eurasian (AM, AZ, BY, KG, KZ, MD, RU, TJ, TM), European (AT, BE, BG, CH, CY, CZ, DE, DK, EE, ES, FI, FR, GB, GR, HU, IE, IT, LU, MC, NL, PT, RO, SE, SI, SK. TR), OAPI (BF, BJ, CF, CG, CI, CM, GA, GN, GQ, GW, ML, MR, NE, SN, TD, TG).

Declarations under Rule 4.17:

- as to applicant's entitlement to apply for and be granted a patent (Rule 4.17(ii)) for all designations
- as to the applicant's entitlement to claim the priority of the earlier application (Rule 4.17(iii)) for all designations
- of inventorship (Rule 4.17(iv)) for US only

Published:

- with international search report
- (88) Date of publication of the international search report: 9 December 2004

For two-letter codes and other abbreviations, refer to the "Guidance Notes on Codes and Abbreviations" appearing at the beginning of each regular issue of the PCT Gazette.

(54) Title: USE OF SENDAI VIRUS AS A HUMAN PARAINFLUENZA VACCINE

(57) Abstract: Immunogenic compositions to protect against human parainfluenza (hPIV) virus infection are provided. The compositions comprise an unmodified Sendai virus that can be safely administered to human subjects, particularly young children, to protect against symptoms and health risks associated with hPIV infection.

INTERNATIONAL SEARCH REPORT

PCT/US04/00635

CLASSIFICATION OF SUBJECT MATTER PCC7 : AGIK 3912; C12Q 1/70 US CL : 424211.1; 43525 B. FELIOS SEARCHED Minimum documentation searched (classification (PC) or to both national classification symbols) U.S.: 424/211.1; 435/5 Documentation searched other than minimum documentation to the extent that such documents are included in the fields searched Leictronic data base consulted during the international search (name of data base and, where practicable, search terms used) Please Sec Continuation Sheet C. DOCUMENTS CONSIDERED TO BE RELEVANT Category * Citation of document, with indication, where appropriate, of the relevant passages Relevant to claim No. X Derived from Currently Prevailing Sendal Virus, Journal of Virology (May 1994, Vol. 68, No. 5, Pages 3369-3373, especially abstract and page 3370-3371, bridging paragraph. A MURPHY et al. Live-attenuated virus vaccines for respiratory syncytial and parainfluenza viruses: applications of reverse genetics, Journal of Clinical Investigation, July 2002, Vol. 110, No. 1, pages 21-27, entire document. *** Secular eaglestion or parain published on or after the insernational fling date or priority respectively and paths and considered to be of paraclast relevance and probles defined to understand be of parallel relevance and paths of the comment of the same paths of the counter of paths of the comment of the same paths of the counter of the same	CT A	COVERA LETTONI OR CURRENCE LA COMPANIA					
US CI. 424/21.11; 435/5 According to International Parter Classification (IPC) or to both national classification and IPC B. FIELDS SEARCHED Minimum documentation searched (classification system followed by classification symbols) U.S.: 424/21.11; 435/5 Documentation searched other than minimum documentation to the extent that such documents are included in the fields searched Electronic data base consulted during the international search (name of data base and, where practicable, search terms used) Please Sec Continuation Sheet C. DOCUMENTS CONSIDERED TO BE RELEVANT Category * Citation of document, with indication, where appropriate, of the relevant passages Relevant to claim No. X WANG et al. A Process Activation Mutant, MCVESI, as a Safe and Potent Live Vaccine Derived from Currently Prevailing Sendai Virus, Journal of Virology, May 1994, Vol. 68, No. 5, Pages 336-3376, sepecially abstract and page 3370-3371, bridging paragraph. A MURPHY et al. Live-attenuated virus vaccines for respiratory syncytial and paraintifuenza viruses: applications of reverse genetics, Journal of Clinical Investigation, July 2002, Vol. 110, No. 1, pages 21-27, entire document. *** **Special categories of cited documents: *** ** ** ** ** ** ** ** **							
According to International Patent Classification (PC) or to both national classification and IPC							
FIELDS SEARCHED	1	• • • •		idii TDG			
Minimum documentation searched (classification system followed by classification symbols) U.S.: 4247211.1; 43575 Documentation searched other than minimum documentation to the extent that such documents are included in the fields searched with the property of the continuation of the extent that such documents are included in the fields searched letters of the continuation sheet Electronic data base consulted during the international search (name of data base and, where practicable, search terms used) Please See Continuation Sheet C. DOCUMENTS CONSIDERED TO BE RELEVANT Category * Cliation of document, with indication, where appropriate, of the relevant passages Relevant to claim No. No. 5, Pages 3369-3379, especially abstract and pages 3370-3371, bridging pages 3370-3371, bridging pages 3370-3371, bridging pages 3370-3371, bridging bastract and pages 3370-337							
U.S.: 424/211.1; 435/5 Documentation searched other than minimum documentation to the extent that such documents are included in the fields searched Electronic data base consulted during the international search (name of data base and, where practicable, search terms used) Please See Continuation Sheet C. DOCUMENTS CONSIDERED TO BE RELEVANT Category * Citation of document, with indication, where appropriate, of the relevant passages X WANG et al. A Protease Activation Mutant, MCVESI, as a Safe and Potent Live Vaccine Derived from Currently Prevailing Sendai Virus, Journal of Virology, May 1994, Vol. 68, No. 5, Pages 3369-3373, especially abstract and page 3370-3371, bridging paragraph. A MURPHY et al. Live-attenuated virus vaccines for respiratory syncyrial and parainfluenza viruses: applications of reverse genetics, Journal of Clinical Investigation, July 2002, Vol. 110, No. 1, pages 21-27, entire document. * Seed lates gotes of field documents ** document defining the general state of the art which is not considered to be of particular relevance of particular relevance ** carrier application or patent published on or after the international filing date ** document of particular relevance, the claimed invention cannot be considered to the internation attended to establish the publication date of another claimfor or which is like tied to establish the publication date of another claimfor or other means ** document or particular relevance, the claimed invention cannot be considered to limit the another claim or patently stap when the document is a inventive step when the document is a town and comment in a inventive step when the document is a town and the comment of particular relevance, the claimed invention cannot be considered to inventive and the considered to inventive and the another claimed in the art of the particular relevance in the claimed invention cannot be considered to inventive an inventive step when the document is town and the comment is an inventive step when the document is tow	B. FIEL	LDS SEARCHED		<u> </u>			
Electronic data base consulted during the international search (name of data base and, where practicable, search terms used) Please See Continuation Sheet C. DOCUMENTS CONSIDERED TO BE RELEVANT Category * Citation of document, with indication, where appropriate, of the relevant passages Relevant to claim No. X WANG et al. A Protease Activation Mutant, MCVESI, as a Safe and Potent Live Vaccine Derived from Currently Prevailing Sendal Virus, Journal of Virology, May 1944, Vol. 68, No. 5, Pages 3369-3373, especially abstract and page 3370-3371, bridging paragraph. A MURPHY et al. Live-attenuated virus vaccines for respiratory syncytial and parainfluenza viruses: applications of reverse genetics, Journal of Clinical Investigation, July 2002, Vol. 110, No. 1, pages 21-27, entire document. ** Special caegories of clud documents: "A" document defining the general state of the art which is not concidered to be of particular relevance. "E" earlier application or parent published on or after the international filing date to priority date and no in conflict with the application cannot be considered to involve an inventive sepwhen the document of particular relevance; the claimed invention cannot be considered to involve an inventive sepwhen the document is taken alone. **Commissioner for parent published or or the international filing date to the property date and not in conflict with the application cannot be considered to involve an inventive sepwhen the document of particular relevance; the claimed invention cannot be considered to involve an inventive sepwhen the document is taken alone. """ **Commissioner for parent published prior to the international filing date to the laternational filing date to the laternatio			by classif	ication symbols)			
Please See Continuation Sheet C. DOCUMENTS CONSIDERED TO BE RELEVANT Category * Citation of document, with indication, where appropriate, of the relevant passages Relevant to claim No. X WANG et al. A Protease Activation Mutant, MCVESI, as a Safe and Potent Live Vaccine Derived from Currently Prevailing Sendai Virus, Journal of Virology, May 1994, Vol. 68, No. 5, Pages 3369-3373, especially abstract and page 3370-3371, bridging paragraph. A MURPHY et al. Live-attenuated virus vaccines for respiratory syncytial and parainfluenza viruses: applications of reverse genetics, Journal of Clinical Investigation, July 2002, Vol. 110, No. 1, pages 21-27, entire document. * Special categories of clied documents: *A* document defining the general state of the art which is not considered to be of particular relevance of the centalists the published on or after the international filing date with the splication but clied to understand the relationship to the international filing date with the splication of particular relevance; the claimed invention cannot be considered to lowelve an inventive step when the document is taken allowed to a period virus of the published of or a fer the international filing date with the splication of the international filing date but later than the pribrity date claimed invention cannot be considered to be caused that the published of or other special reason (as specifics) **Comment referring to an oral disclosure, use, exhibition or other special reason (as specifics) **Of document referring to an oral disclosure, use, exhibition or other special reason (as specifics) **Of document referring to an oral disclosure, use, exhibition or other special reason (as specifics) **Of document referring to an oral disclosure, use, exhibition or other special reason (as specifics) **Of document referring to an oral disclosure, use, exhibition or other special reason (as specifics) **Of document referring to an oral disclosure, use, exhibition or other special reason (as specifics) **Of document	1	ion searched other than minimum documentation to the	e extent th	at such documents are included i	n the fields searched		
Category * Citation of document, with indication, where appropriate, of the relevant passages X WANG et al. A Protease Activation Mutant, MCVESI, as a Safe and Potent Live Vaccine Derived from Currently Prevailing Sendai Virus, Journal of Virology, May 1994, Vol. 68, No. 5, Pages 3369-3373, especially abstract and page 3370-3371, bridging paragraph. A WIRPHY et al. Live-attenuated virus vaccines for respiratory syncytial and parainfluenza viruses: applications of reverse genetics, Journal of Clinical Investigation, July 2002, Vol. 110, No. 1, pages 21-27, entire document. * Special categories of clied documents: "A" document defining the general state of the art which is not considered to be of particular relevance "e" earlier application or patert published on or after the international filing date of particular relevance "c" document which may throw doubts on priority claim(s) or which is clied to establish the publication date of another cliation or other special reason (as specified) "O" document referring to an oral disclosure, use, exhibition or other means "b" document published prior to the international filing date but later than the priority date claimed "Comment published prior to the international filing date but later than the proficity date claimed Date of the actual completion of the international search 24 August 2004 (24.08.2004) Name and mailing address of the ISA/US Mail Sup PCT, Artn: ISA/US Commissioner for Patents P.O. Box 1430 Alexandria, Wirginia 22313-1450 Racismile No. (703) 303-3230			ne of data	base and, where practicable, sear	rch terms used)		
WANG et al. A Protease Activation Mutant, MCVES1, as a Safe and Potent Live Vaccine Derived from Currently Prevailing Sendai Virus, Journal of Virology, May 1994, Vol. 68, No. 5, Pages 3369-3373, especially abstract and page 3370-3371, bridging paragraph. MURPHY et al. Live-attenuated virus vaccines for respiratory syncytial and parainfluenza viruses: applications of reverse genetics, Journal of Clinical Investigation, July 2002, Vol. 110, No. 1, pages 21-27, entire document. *Special categories of clied documents: "A" document defining the general state of the art which is not considered to be of particular relevance of particular relevance of particular relevance which may throw doubs on priority claim(s) or which Is cited to establish the publication due of another cliation or other special reason (as specified) "O" document which may throw doubs on a priority claim(s) or which Is cited to establish the publication due of another cliation or other special reason (as specified) "O" document referring to an oral disclosure, use, exhibition or other means "P" document published prior to the international filing date or priority date and not in conflict with the application but clied to understand the principal transparency of particular relevance; the claimed invention cannot be considered to involve an inventive step when the document is document upublished prior to the international filing date but later than the priority data in inventive step when the document is combined with one or more other such documents, such combination being obvious to a person inventive step when the document is combined with one or more other such document such combination being obvious to a person inventive step when the document to combined with one or more other such document such combination being obvious to a person inventive step when the document to combined with one or more other such document to combined with one or more other such document member of the same patent family Date of the actual completion of the inter	C. DOC	UMENTS CONSIDERED TO BE RELEVANT					
WANG et al. A Protease Activation Mutant, MCVES1, as a Safe and Potent Live Vaccine Derived from Currently Prevailing Sendai Virus, Journal of Virology, May 1994, Vol. 68, No. 5, Pages 3369-3373, especially abstract and page 3370-3371, bridging paragraph. MURPHY et al. Live-attenuated virus vaccines for respiratory syncytial and parainfluenza viruses: applications of reverse genetics, Journal of Clinical Investigation, July 2002, Vol. 110, No. 1, pages 21-27, entire document. *Special categories of cited documents: "A" document defining the general state of the art which is not considered to be of particular relevance. "E" earlier application or patent published on or after the international filing date or priority date and not in conflict with the application but cited to understand the principal term of particular relevance, the claimed invention cannot be considered to lively on a inventive step when the document to exhibit the publication date of another clainton or other special reason (as specified). "O" document which may throw doubs on priority claim(s) or which is cited to establish the publication date of another claim(s) or which is cited to establish the publication and the publication of the international filing date but later than the priority date claimed "O" document referring to an oral disclosure, use, exhibition or other means "P" document published prior to the international filing date but later than the principal date of another claim(s) or which is cited to establish the publication date of another claim(s) or which is cited to establish the publication of particular relevance, the claimed invention cannot be considered to involve an inventive step when the document is combined with one or more other such document such combination being obvious to a person allowed the comment is an inventive step when the document is combined with one or more other such document on particular relevance, the claimed invention cannot be considered to involve an inventive step when the document is co	Category *	Citation of document, with indication, where	appropriate	e, of the relevant passages	Relevant to claim No.		
MURPHY et al. Live-attenuated virus vaccines for respiratory syncytial and parainfluenza viruses: applications of reverse genetics, Journal of Clinical Investigation, July 2002, Vol. 110, No. 1, pages 21-27, entire document. * Special categories of cited documents: * Transport in the special categories of cited documents: * Cocument defining the general state of the art which is not considered to be of particular relevance: * Cocument defining the general state of the art which is not considered to be organized to understand the principle or theory origing the invention cannot be considered to involve an inventive step when the document is taken alone * Coument of particular relevance: the claimed invention cannot be considered to only on a inventive step when the document is taken alone * Transport in the publication or patent published on or after the international filing date * Transport in the published of the special reason (as specified) * Coument of particular relevance; the claimed invention cannot be considered to involve an inventive step when the document is taken alone * Transport in the published prior to the international filing date but later than the priority date claimed * Transport in the published prior to the international filing date but later than the priority date claimed * Transport in the published prior to the international filing date but later than the priority date claimed * Transport in the published prior to the international filing date but later than the priority date claimed * Transport in the published prior to the international filing date but later than the priority date claimed * Transport in the published prior to the international filing date but later than the priority		WANG et al. A Protease Activation Mutant, MCV Derived from Currently Prevailing Sendai Virus, Jo	ES1, as a sournal of V	Safe and Potent Live Vaccine /irology, May 1994, Vol. 68,			
* Special categories of cited documents: "A" document defining the general state of the art which is not considered to be of particular relevance "E" earlier application or patent published on or after the international filing date or priority date and not in conflict with the application but cited to understand the principle or theory underlying the invention cannot be considered novel or cannot be considered to involve an inventive step when the document is taken alone "Y" document of particular relevance; the claimed invention cannot be considered to involve an inventive step when the document is combined with one or more other such document is combined with one or more other such documents, such combination being obvious to a person skilled in the art "P" document published prior to the international filing date but later than the priority date claimed Date of the actual completion of the international search 24 August 2004 (24.08.2004) Name and mailing address of the ISA/US Mail Stop PCT, Attn: ISA/US Commissioner for Patents P.O. Box 1450 Alexandria, Virginia 22313-1450 Facsimile No. (703) 305-3230	A	MURPHY et al. Live-attenuated virus vaccines for viruses: applications of reverse genetics, Journal of	respirator	y syncytial and parainfluenza	1-16		
"A" document defining the general state of the art which is not considered to be of particular relevance "E" earlier application or patent published on or after the international filing date "L" document which may throw doubts on priority claim(s) or which is cited to establish the publication date of another citation or other special reason (as specified) "O" document referring to an oral disclosure, use, exhibition or other means "P" document published prior to the international filing date but later than the priority date claimed Date of the actual completion of the international search 24 August 2004 (24.08.2004) Name and mailing address of the ISA/US Mail Stop PCT, Attn: ISA/US Commissioner for Patents P.O. Box 1450 Alexandria, Virginia 22313-1450 Facsimile No. (703) 305-3230					rnational filing date or priority		
"L" document which may throw doubts on priority claim(s) or which is cited to establish the publication date of another citation or other special reason (as specified) "O" document referring to an oral disclosure, use, exhibition or other means "P" document published prior to the international filing date but later than the priority date claimed Date of the actual completion of the international search 24 August 2004 (24.08.2004) Name and mailing address of the ISA/US Mail Stop PCT, Attn: ISA/US Commissioner for Patents P.O. Box 1450 Alexandria, Virginia 22313-1450 Facsimile No. (703) 305-3230 Alexandria, Virginia 22313-1450 Alexandria, Virginia 22313-1450 Facsimile No. (703) 305-3230 Commissioner for Patents P.O. Box 1450 Alexandria, Virginia 22313-1450 Facsimile No. (703) 305-3230 Commissioner for Patents P.O. Box 1450 Alexandria, Virginia 22313-1450 Facsimile No. (703) 305-3230 Commissioner for Patents P.O. Box 1450 Alexandria, Virginia 22313-1450 Facsimile No. (703) 305-3230 Commissioner for Patents P.O. Box 1450 Alexandria, Virginia 22313-1450 Facsimile No. (703) 305-3230	"A" document defining the general state of the art which is not considered to be			date and not in conflict with the application but cited to understand the principle or theory underlying the invention			
establish the publication date of another citation or other special reason (as specified) "O" document referring to an oral disclosure, use, exhibition or other means "P" document published prior to the international filing date but later than the priority date claimed Date of the actual completion of the international search 24 August 2004 (24.08.2004) Name and mailing address of the ISA/US Mail Stop PCT, Attn: ISA/US Commissioner for Patents P.O. Box 1450 Alexandria, Virginia 22313-1450 Facsimile No. (703) 305-3230 "Y" document of particular relevance; the claimed invention cannot be considered to involve an inventive step when the document is combined with one or more other such documents, such combination being obvious to a person skilled in the art document member of the same patent family Date of mailing of the international search report 22 SEP 2004 Authorized officer Stacy B Chen Telephone No. 703-308-0196	- The state of the		"X"	considered novel or cannot be considered to involve an inventive step when the document is taken alone document of particular relevance; the claimed invention cannot be considered to involve an inventive step when the document is			
"P" document published prior to the international filing date but later than the priority date claimed Date of the actual completion of the international search 24 August 2004 (24.08.2004) Name and mailing address of the ISA/US Mail Stop PCT, Attn: ISA/US Commissioner for Patents P.O. Box 1450 Alexandria, Virginia 22313-1450 Facsimile No. (703) 305-3230 Alexandria being obvious to a person skilled in the art document member of the same patent family Date of mailing of the international search report 22 SEP 2004 Authorized office: Stacy B Chen Telephone No. 703-308-0196	establish the publication date of another citation or other special reason (as		"Y"				
priority date claimed Date of the actual completion of the international search 24 August 2004 (24.08.2004) Name and mailing address of the ISA/US Mail Stop PCT, Attn: ISA/US Commissioner for Patents P.O. Box 1450 Alexandria, Virginia 22313-1450 Facsimile No. (703) 305-3230 Date of mailing of the international search report 22 SEP 2004 Authorized officer Stacy B Chen Telephone No. 703-308-0196	"O" document	referring to an oral disclosure, use, exhibition or other means		being obvious to a person skilled in the	e art		
22 SEP 2004 Name and mailing address of the ISA/US Mail Stop PCT, Attn: ISA/US Commissioner for Patents P.O. Box 1450 Alexandria, Virginia 22313-1450 Facsimile No. (703) 305-3230 Authorized officer Stacy B Chen Telephone No. 703-308-0196				document member of the same patent family			
Name and mailing address of the ISA/US Mail Stop PCT, Attn: ISA/US Commissioner for Patents P.O. Box 1450 Alexandria, Virginia 22313-1450 Facsimile No. (703) 305-3230 Authorized offices Stacy B Chen Telephone No. 703-308-0196			Date of mailing of the international search report 22 SEP 2004				
Mail Stop PCT, Attn: ISA/US Commissioner for Patents P.O. Box 1450 Alexandria, Virginia 22313-1450 Facsimile No. (703) 305-3230 Telephone No. 703-308-0196			Aithani	ad offices			
P.O. Box 1450 Alexandria, Virginia 22313-1450 Facsimile No. (703) 305-3230 Telephone No. 703-308-0196		•	12/0	rettua. Lula	anian (
Alexandria, Virginia 22313-1450 Telephone No. 703-308-0196 Facsimile No. (703) 305-3230	Соп	nmissioner for Patents	Stacy B	Chen Chen Chen Chen Chen Chen Chen Chen	The San		
Facsimile No. (703) 305-3230			Telepho	ne No. 703-308-0196	401		
			'				
			L				

	International application No.	
INTERNATIONAL SEARCH REPORT	PCT/US04/00635	
}		
	·	
Continuation of B. FIELDS SEARCHED Item 3:		
EAST, CASONLINE, MEDIJNE, BIOSIS EMBASE CAPILIS SCISEARCH		
I search terms: hurwitz, slobod, portner, colectough; sendai, human parainfluenza, h	piv, piv, immunization, vaccination, cross-	
protection, respiratory, t-cell response		
	İ	
•		
	i	
	İ	